Teva's 2013 outlook misses estimates
Nov 30 (Reuters) - Teva Pharmaceutical Industries Ltd , the world's biggest generic drugmaker, forecast profit and revenue for the calendar 2013 that fell short of analysts' estimates.
The Israel-based company, which posted a quarterly profit above market estimates earlier this month on strong U.S. revenue, expects an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.
Analysts were expecting earnings of $5.71 per share, on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky in Germany after pardon
- Investigators look overseas for hackers in Target case: source
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter